An evaluation demonstrating continued efficacy and improved safety and tolerability in 17 patients switched to PEGASYS® after discontinuation from REBETRONTM for the treatment of chronic hepatitis C
2000 ◽
Vol 39
(3)
◽
pp. 212-214
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):